Regorafenib in previously treated metastatic colorectal cancer

The multikinase inhibitor regorafenib was recently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, for patients with wild-type KRAS tumors, anti-EGFR therapy.¹ Regorafenib inhibits numerous membrane-bound and intracellular kinases involved in normal cell function and in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment (including RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR- , PDGFR- , FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl kinases). The approval was based on findings in the international, phase 3 CORRECT trial²…

*Click on the links to the left of this introduction for a PDF of the full article and related Commentary.  

The multikinase inhibitor regorafenib was recently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, for patients with wild-type KRAS tumors, anti-EGFR therapy.¹ Regorafenib inhibits numerous membrane-bound and intracellular kinases involved in normal cell function and in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment (including RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR- , PDGFR- , FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl kinases). The approval was based on findings in the international, phase 3 CORRECT trial²…

*Click on the links to the left of this introduction for a PDF of the full article and related Commentary.  

The multikinase inhibitor regorafenib was recently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, for patients with wild-type KRAS tumors, anti-EGFR therapy.¹ Regorafenib inhibits numerous membrane-bound and intracellular kinases involved in normal cell function and in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment (including RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR- , PDGFR- , FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl kinases). The approval was based on findings in the international, phase 3 CORRECT trial²…

*Click on the links to the left of this introduction for a PDF of the full article and related Commentary.